{"nctId":"NCT00089661","briefTitle":"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer","startDateStruct":{"date":"2004-10-01","type":"ACTUAL"},"conditions":["Breast Cancer","Low Bone Mineral Density","Osteopenia"],"count":252,"armGroups":[{"label":"AMG 162 / Denosumab","type":"EXPERIMENTAL","interventionNames":["Drug: AMG 162 / Denosumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"AMG 162 / Denosumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"* Histologically or cytologically confirmed adenocarcinoma of the breast\n* Subjects with early stage disease who are estrogen receptor positive and who have completed their treatment pathway (surgery, chemo-therapy, radiation, and/or hormone therapy) and are currently on or will initiate aromatase inhibitor therapy, and are expected to stay on aromatase inhibitor therapy for the duration of the 24-month study\n* All treatment pathway must be completed ≥ 4 weeks prior to study entry, and all acute toxic effect of any above therapy must be resolved to ≤ Grade 1 by National Cancer Institution (NCI) Common Terminology Criteria for Adverse Events (CTCAE)\n* Female \\> 18 years of age\n* ECOG Performance status 0 and 1\n* Lumbar spine, total hip or femoral neck BMD equivalent to a t-score classification of -1.0 to -2.5\n* Subject is willing and able to provide signed consent before any study-specific procedure\n\nOther criteria also apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12","description":"Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"-.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6","description":"Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"-.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","description":"Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"-.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Hip Bone Mineral Density Percent Change From Baseline at Month 6","description":"Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"-.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12","description":"Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"-.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 6","description":"Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"-.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":120},"commonTop":["Arthralgia","Fatigue","Back pain","Pain in extremity","Constipation"]}}}